Phase 3 Overweight Clinical Trials
46 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 46 trials
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
ObesityOverweight
Kailera1,800 enrolled33 locationsNCT07284875
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Obesity With DiabetesOverweight With Diabetes
Kailera1,700 enrolled37 locationsNCT07284901
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes MellitusObesityOverweight
Novo Nordisk A/S630 enrolled73 locationsNCT07533175
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled28 locationsNCT07351045
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
ObesityOverweight
Eli Lilly and Company125 enrolled50 locationsNCT06672549
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightOverweight and/or Obesity
Pfizer999 enrolled184 locationsNCT07400653
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Chronic Low Back Pain (CLBP)ObesityOverweight
Eli Lilly and Company586 enrolled41 locationsNCT07035093
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459